P25A

Pimavanserin is a 5-HT_2A receptor inverse agonist as the first and only drug approved for the treatment of Parkinson's disease psychosis (PDP), which has a black box warning regarding an increased risk of death in elderly patients with dementia-related psychosis and warning related to QTc interval prolongation. In this article, a total of 25 novel modulated pimavanserin derivatives were designed and synthesized. The optimal compound P25a exhibited better 5-HT_2A receptor inverse agonist activity and lower hERG inhibition than that of pimavanserin. Molecular dynamics simulations also indicated that compound P25a had a more stable binding mode with the receptor. Moreover, compound P25a exhibited almost 2.2-fold AUC_last increasement in in vivo pharmacokinetics study with higher exposure in brain and lower distribution in cardiac tissue. Compound P25a demonstrated higher functional activities in both DOI-induced head twitches model and MK801-induced hyperactivity model. In conclusion, the enhanced in vitro and in vivo efficacy profiles, minimal hERG inhibition, and superior tissue distribution, established compound P25a as a promising preclinical candidate for treatment of PDP that warranted further investigation.